January 14, 2025 – Talk Bio

Umoja Biopharma Advances In Situ CAR-T Therapy with FDA Clearance and $100M Series C Funding

3 months ago talkbio0Tagged CAR-T, Clearance, Hematologic Neoplasms, in situ, Series, UB-VV111, Umoja Biopharma, United States Food and Drug Administration

Umoja Biopharma, CAR-T therapy, in situ, UB-VV111, FDA clearance, hematologic malignancies, Series C funding

Truveta Genome Project: A Historic 10M Genome Sequencing Initiative Backed by Regeneron, Illumina, and Leading Health Systems

3 months ago talkbio0Tagged Drug Discovery, genetic sequencing, genome sequencing, Genotype, healthcare analytics, Illumina, phenotypic, Precision Medicine, Regeneron, Truveta

Truveta Genome Project, 10M genome sequencing, Regeneron, Illumina, genetic sequencing, genotypic and phenotypic data, healthcare analytics, drug discovery, personalized medicine.

Denali and AbbVie’s ALS Candidates Fail Phase 2/3 Trials, Highlighting Challenges in ALS Research

3 months ago talkbio0Tagged AbbVie, Amyotrophic Lateral Sclerosis, Calico Life Sciences, Clinical Trials, Denali, DNL343, Drug Development, fosigotifator, HEALEY

ALS, Denali Therapeutics, AbbVie, Calico Life Sciences, HEALEY ALS Platform Trial, DNL343, fosigotifator, amyotrophic lateral sclerosis, clinical trials, drug development